BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

461 related articles for article (PubMed ID: 32557398)

  • 21. Improving outcomes and quality of life for patients with transfusion-dependent β-thalassemia: recommendations for best clinical practice and the use of novel treatment strategies.
    Taher AT; Bou-Fakhredin R; Kattamis A; Viprakasit V; Cappellini MD
    Expert Rev Hematol; 2021 Oct; 14(10):897-909. PubMed ID: 34493145
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Challenges of blood transfusions in β-thalassemia.
    Shah FT; Sayani F; Trompeter S; Drasar E; Piga A
    Blood Rev; 2019 Sep; 37():100588. PubMed ID: 31324412
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Revisiting beta thalassemia intermedia: past, present, and future prospects.
    Ben Salah N; Bou-Fakhredin R; Mellouli F; Taher AT
    Hematology; 2017 Dec; 22(10):607-616. PubMed ID: 28589785
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of the aging beta-thalassemia transfusion-dependent population - The Italian experience.
    Pinto VM; Poggi M; Russo R; Giusti A; Forni GL
    Blood Rev; 2019 Nov; 38():100594. PubMed ID: 31416718
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hemoglobin disorders: lentiviral gene therapy in the starting blocks to enter clinical practice.
    Sii-Felice K; Giorgi M; Leboulch P; Payen E
    Exp Hematol; 2018 Aug; 64():12-32. PubMed ID: 29807062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preclinical transfusion-dependent humanized mouse model of beta thalassemia major.
    Huo Y; McConnell SC; Ryan TM
    Blood; 2009 May; 113(19):4763-70. PubMed ID: 19258591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron overload in thalassemia: different organs at different rates.
    Taher AT; Saliba AN
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):265-271. PubMed ID: 29222265
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management.
    Vichinsky E
    Curr Med Res Opin; 2016; 32(1):191-204. PubMed ID: 26479125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alpha- and Beta-thalassemia: Rapid Evidence Review.
    Baird DC; Batten SH; Sparks SK
    Am Fam Physician; 2022 Mar; 105(3):272-280. PubMed ID: 35289581
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Iron overload and iron-chelating therapy in hemoglobin E-beta thalassemia.
    Olivieri NF; De Silva S; Premawardena A; Sharma S; Viens AM; Taylor CM; Brittenham GM; Weatherall DJ
    J Pediatr Hematol Oncol; 2000; 22(6):593-7. PubMed ID: 11132236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transferrin receptor 2 is a potential novel therapeutic target for β-thalassemia: evidence from a murine model.
    Artuso I; Lidonnici MR; Altamura S; Mandelli G; Pettinato M; Muckenthaler MU; Silvestri L; Ferrari G; Camaschella C; Nai A
    Blood; 2018 Nov; 132(21):2286-2297. PubMed ID: 30209118
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Challenges in chronic transfusion for patients with thalassemia.
    Lal A
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):160-166. PubMed ID: 33275743
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
    Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
    Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Thalassemia.
    Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
    Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Retinal abnormalities in β-thalassemia major.
    Bhoiwala DL; Dunaief JL
    Surv Ophthalmol; 2016; 61(1):33-50. PubMed ID: 26325202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Thalassemia Major: Transplantation or Transfusion and Chelation.
    Mohamed SY
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):290-298. PubMed ID: 28651066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interaction of Transfusion and Iron Chelation in Thalassemias.
    Porter JB; Garbowski MW
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):247-259. PubMed ID: 29458730
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel therapies in β-thalassaemia.
    Grech L; Borg K; Borg J
    Br J Clin Pharmacol; 2022 Jun; 88(6):2509-2524. PubMed ID: 34004015
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
    Marsella M; Borgna-Pignatti C
    Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. β-Thalassemia: evolving treatment options beyond transfusion and iron chelation.
    Langer AL; Esrick EB
    Hematology Am Soc Hematol Educ Program; 2021 Dec; 2021(1):600-606. PubMed ID: 34889443
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.